MOTILAL OSWAL



NIFTY50
16,451

Stock Info	
CMP (INR)	2,097
TP (INR)	2,350
M-cap. (INR b)	286
Avg. Turnover, INR m	2,859
Equity Shares (m)	136
Face Value	2
52-Week Range (INR)	2,209/605
1/6/12 m Abs. Perf* (%)	10/ 64/229
Data as on 20 th Aug'21	

Financial Snapshot (INR b)


Y/E March	FY21	FY22E	FY23E
Sales	43.6	54.4	62.3
EBITDA	12.5	14.6	16.3
Adj. PAT	7.8	9.5	10.7
EBIT Margin (%)	25.1	23.5	22.8
EPS (INR)	56.9	69.4	78.2
EPS Gr. (%)	27.0	21.9	12.7
BV/Sh. (INR)	172	231	297
RoE (%)	39.6	34.4	29.6


Valuations

36.9	30.2	26.8
23.3	19.8	17.5
6.7	5.3	4.6
0.3	0.5	0.6
0.03	0.01	0.02
	23.3 6.7 0.3	23.3 19.8 6.7 5.3 0.3 0.5

Shareholding pattern (%)

As on	Dec'20	Mar'21	Jun'21
Promoter	45.7	45.7	45.7
MFs	9.0	10.1	8.3
FPIs	13.3	11.9	11.4
Others	32.0	32.3	34.6





Investors are advised to refer through disclosures made at the end of the Research Report.

Focus on advance/high value products intensifies

Deepak Nitrite (DN) is an intermediate chemical company, with a diversified business of Basic Chemicals, Fine and Specialty Chemicals, and Performance Products. It manufactures phenol, acetone and isopropyl alcohol (IPA) through its subsidiary, Deepak Phenolics (DPL).

Achieved huge success with DPL: To substitute imports, DN started commercial production of phenol, acetone, and IPA in CY18 through DPL. It has established itself as the most reliable player, with a domestic market share of ~65% in the first year itself. Huge opportunities lie ahead for DPL as phenol plants in the US are facing challenges. China has also started importing phenols. Imports into India are seeing strong growth due to lack of supply and higher freight rates (expect domestic demand CAGR of 10-12%). We believe debottlenecking capex or additional expansion would lead to huge growth in this segment. Further, with objective of moving into value-added downstream products, with captive raw material consumption, DPL is doubling its IPA manufacturing plant capacity to 60ktpa (likely to commission in 1HFY22), which would result in further import substitution.

Fine and Specialty Chemicals to drive growth for DN: Backed by a diversified portfolio mix, DN continues to leverage export demand for Fine and Specialty Chemicals as large global customers shift to high-quality products and diversify away from China. It recently launched two products in Pharma and Agrochemicals, respectively. The management expects this segment to deliver stellar performance in coming years, realizing the solid gains accruing from further integration initiatives and capacity expansion in established products. In Basic Chemicals, it would continue leveraging its cost leadership position to drive market share gains.

Transition to an advanced products company: DN aims to transition from a chemical intermediates company to an advanced products one (it is leaning towards Life Sciences, which is the need of the hour). It would continue to focus on launching more products under the Fine and Specialty segment and close the gaps in its production value chain. Around 125 acres of land at Dahej (called Dahej-II) would be developed to focus primarily on advance specialty/intermediates in the Life Sciences segment, especially in Fluorination. In addition to an annual capex plan of INR4b in DN, the board has approved further investments in DPL: a) INR3.5b in specialty intermediates, and b) INR7b in downstream products (for higher production of Solvents). It aims to be the largest player in Solvents and capitalize on import substitution. The increased focus on advance/high value products would aid margin expansion, sustainability and may even command a higher valuation multiple.


Valuation and view: DN has the most lucrative profile in the entire Specialty Chemicals space. The management said it would facilitate import substitution, with further integration in current processes. The commissioning of IPA expansion and the captive power plant are expected by the end of 1HFY22. The captive power plant would increase DPL's competitiveness in this segment. A recovery in demand in OBA and DASDA (i.e. Performance Chemicals) is expected over FY22, while demand for Agrochemical and Personal Care products continue to remain robust. Despite a capex plan of INR18b over the next three years, it is expected to turn net cash positive by FY23E, with an FCF generation of INR17.4b over FY22-24E. We maintain our Buy rating, with one of the best RoE profiles in our coverage universe.

Siddhartha Khemka – Research Analyst

23 August 2021

Story in charts

Exhibit 1: DPL constitutes over 58% of consolidated revenue, Exhibit 2: EBITDA margin to normalize from FY21 levels likely to stay at current levels (revenue mix %)



Source: Company, MOFSL









Exhibit 4: Expect 17% CAGR over FY21-23E



Source: Company, MOFSL





Financials and valuations

Income Statement						(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22E	FY23E
Total Income from Operations	16,762	26,999	42,297	43,598	54,443	62,312
Change (%)	15.2	61.1	56.7	3.1	24.9	14.5
Gross Margin (%)	38.0	39.0	43.9	48.1	45.3	44.3
EBITDA	1,963	4,139	10,258	12,470	14,576	16,273
Margin (%)	11.7	15.3	24.3	28.6	26.8	26.1
Depreciation	526	778	1,397	1,526	1,792	2,056
EBIT	1,437	3,361	8,861	10,944	12,784	14,217
Int. and Finance Charges	451	832	1,149	742	358	220
Other Income	123	151	352	215	218	249
PBT bef. EO Exp.	1,109	2,680	8,064	10,417	12,643	14,247
EO Items	0	0	0	0	0	0
PBT after EO Exp.	1,109	2,680	8,064	10,417	12,643	14,247
Total Tax	318	943	1,954	2,659	3,182	3,586
Tax Rate (%)	28.7	35.2	24.2	25.5	25.2	25.2
Reported PAT	790	1,737	6,110	7,758	9,461	10,661
Adjusted PAT	790	1,737	6,110	7,758	9,461	10,661
Change (%)	72.4	119.8	251.9	27.0	21.9	12.7
Margin (%)	4.7	6.4	14.4	17.8	17.4	17.1

Balance Sheet						(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22E	FY23E
Equity Share Capital	273	273	273	273	273	273
Total Reserves	8,949	10,443	15,446	23,194	31,235	40,297
Net Worth	9,221	10,716	15,719	23,467	31,508	40,570
Total Loans	9,866	12,286	10,279	5,271	3,690	2,583
Deferred Tax Liabilities	454	775	796	1,078	1,078	1,078
Capital Employed	19,541	23,776	26,794	29,816	36,276	44,231
Gross Block	6,403	17,749	20,460	22,304	28,304	34,304
Less: Accum. Deprn.	528	743	2,140	3,666	5,459	7,514
Net Fixed Assets	5,875	17,006	18,320	18,637	22,845	26,790
Capital WIP	9,545	339	1,723	2,068	2,068	2,068
Total Investments	318	24	24	1,893	1,893	1,893
Curr. Assets, Loans, and Adv.	10,167	11,910	12,019	13,005	16,126	21,145
Inventory	3,272	4,107	3,945	3,827	4,909	5,669
Account Receivables	4,118	5,750	6,127	7,563	7,887	9,027
Cash and Bank Balance	482	258	314	334	1,229	4,044
Cash	94	30	21	89 <mark>89</mark>	983	3,799
Bank Balance	388	228	293	245	245	245
Loans and Advances	2,296	1,795	1,633	1,281	2,102	2,406
Curr. Liability and Prov.	6,364	5,502	5,292	5,787	6,656	7,664
Account Payables	5,953	4,724	3,643	4,367	4,533	5,234
Other Current Liabilities	280	587	1,385	1,144	1,783	2,041
Provisions	132	191	264	276	340	390
Net Current Assets	3,803	6,408	6,727	7,218	9,471	13,481
Appl. of Funds	19,541	23,776	26,794	29,816	36,276	44,231

E: MOFSL estimates

Y/E Mar	FY18	FY19	FY20	FY21	FY22E	FY23E
Basic (INR)						
EPS	5.8	12.7	44.8	56.9	69.4	78.2
Cash EPS	9.6	18.4	55.0	68.1	82.5	93.2
BV/Share	67.6	78.6	115.2	172.0	231.0	297.4
DPS	1.3	6.5	4.5	5.5	10.4	11.7
Payout (%)	27.0	61.6	12.1	9.7	15.0	15.0
Valuation (x)						
P/E	362.0	164.7	46.8	36.9	30.2	26.8
Cash P/E	217.3	113.8	38.1	30.8	25.4	22.5
P/BV	31.0	26.7	18.2	12.2	9.1	7.1
EV/Sales	17.6	11.0	7.0	6.7	5.3	4.6
ev/ebitda	150.5	72.0	28.9	23.3	19.8	17.5
Dividend Yield (%)	0.1	0.3	0.2	0.3	0.5	0.6
FCF per share	-32.1	-13.3	25.6	58.0	31.2	42.1
Return Ratios (%)						
RoE	9.7	17.4	46.2	39.6	34.4	29.6
RoCE	6.5	10.5	27.6	29.4	29.4	26.9
RoIC	10.7	13.5	28.0	32.4	33.8	31.6
Working Capital Ratios						
Fixed Asset Turnover (x)	2.9	2.4	2.4	2.4	2.6	2.5
Asset Turnover (x)	0.9	1.1	1.6	1.5	1.5	1.4
Inventory (Days)	71	56	34	32	33	33
Debtor (Days)	90	78	53	63	53	53
Creditor (Days)	130	64	31	37	30	31
Leverage Ratio (x)						
Current Ratio	1.6	2.2	2.3	2.2	2.4	2.8
Interest Coverage Ratio	3.2	4.0	7.7	14.7	35.7	64.8
Net Debt/Equity	1.0	1.1	0.6	0.2	0.1	0.0

Cash Flow Statement

Cash Flow Statement						(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22E	FY23E
OP/(Loss) before Tax	1,109	2,680	8,064	10,417	12,643	14,247
Depreciation	528	778	1,397	1,526	1,792	2,056
Others	481	829	1,262	853	358	220
Direct Taxes Paid	-279	-561	-1,985	-2,365	-3,182	-3,586
(Inc.)/Dec. in WC	-9	-3,123	-1,092	-440	-1,358	-1,195
CF from Operations	1,830	603	7,647	9,991	10,254	11,741
(Inc.)/Dec. in FA	-6,206	-2,410	-4,160	-2,086	-6,000	-6,000
Free Cash Flow	-4,376	-1,808	3,487	7,905	4,254	5,741
CF from Investments	-5,247	-1,626	-4,279	-3,962	-6,000	-6,000
Inc./(Dec.) in Debt	2,626	2,033	-1,088	-5,217	-1,581	-1,107
Interest Paid	-450	-841	-1,134	-736	-358	-220
Dividend Paid	-188	-213	-1,060	-4	-1,419	-1,599
CF from Fin. Activity	3,453	958	-3,376	-5,962	-3,359	-2,926
Inc./Dec. in Cash	36	-64	-8	67	895	2,815
Opening Balance	58	94	30	22	89	984
Closing Balance	94	30	22	89	984	3,799

E: MOFSL estimates

This report is intended for distribution to Retail Investors

Explanation of Investment Rating			
Investment Rating	Expected return (over 12-month)		
BUY	>=15%		
SELL	< - 10%		
NEUTRAL	< - 10 % to 15%		
UNDER REVIEW	Rating may undergo a change		
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation		
Disclosures			

Deckers

Discourse are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Molial Oswal Financial Services Ldt. (MOFSL) is a SEBI Resignerd Analyst Regulations 2014 (herein after referred to as the Regulations).

Molial Oswal Financial Services. Lpository participant services. Bepository participant services. Investigned and visuous financial products. MOFSL is a subject ormodity & Correlations Exchange Limited (MOESL) for its sock texhange Limited (ISSE). Mile (ISSE) Mile Mobile) Swal Securities Limited - MOSL) is registered with the Securities & Exchange Beard of India (SEB) and is a registered Trading Member with National Securities Limited - MOSL) is registered with the Securities & Exchange Beard of India (SEB) and is a registered Trading Member with National Securities Limited - MOSL) is registered with the Securities & Exchange Beard of India (SEB) and is care valiable on the website at this full products. MOFSL (enstities Company et India Ldt MISC) for distribution of financial products and Insurance (MISC) Development Autority of India (MCIRA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services LLL are available on the website at this full product services LL are available on the website at this service and the analyst or their indivers may have actual beneficial ownership of 1% or more securities in the subject company of the research Report or date of the public appearance.

Inter relatives may have actual beneficial company of this research report or at the time of publication of the research report.

Inter relatives may have actual beneficial company of this research report or at the time of publication of the research report.

Intereseved compen

Terms & Conditions: This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, expressent information of for the true sources, completeness or correctness. All such information and propose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report. Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the services on sources to his report accurately reflect the personal views expressed in this research report accurately reflect the personal views of the analyst(s) in the service or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the service or issues.

specific recommendations and views expressed by research analyst(s) in this report. Disclosure of Interest Statement Deepak Nitrite Ltd.

Analyst ownership of the stock No A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions. For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors. "Nothing Here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report islare not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S. MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the*1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific institutional lawstors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors". This deponds on relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors. In reliance on the exemption from registrations thereof by the U.S. Securities and Exchange Act of 1944, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Act of 1947 and interpretations thereof by the U.S. Securities and Exchange Act of 1947 and interpretations thereof by the U.S. Securities and Exchange Act of 1947 and interpretations thereof by the U.S. Securities Exchange Act of 1947 as a samended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Act of 1947 and interpretations thereof by the U.S. Securities and Exchange Act of 1947 and interpretations thereof by the U.S. Securities and Exchange Act") in ord to to conduct business with interpretations thereof by the U.S. Securities and Exchange Act of 1947, and inter

based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 2011294012) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore Person is Singapore Person is of accredited "institutional investors, of which some of whom may consist of "accredited" institutional investors as defined in section A4(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, Justice MoCMSPL. Disclaimer.

Milling variable developed methods and used of the Report and Inform MOCMSPL Disclamer. This report is intended for distribution to Retail Investors. The report and information contained herein is sticitly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or or eproduced in any form, withou nor may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a prepresentation that any investment of specific securities or specific circumstances. The securities of companies reference on their own investment of the visuable or appropriate to your specific circumstances. The securities or optimals or greeness of integes of theirs on investment in the securities of companies reference to in this document thoveled), and should consult it so mathwas to the detimate in investment of an investment of a subscribe for severes or any not be subable for all investors. Certain transactions -including the metista and risk involved), and should not be timestigations as it deems necessary to arrive at an independent evaluation of an investment in the securities or dompanies reflected to in this document. The Disclosures of interest Statement incorporated in this document in this document. The organorus. MORE, Lis associates, their directors are differented in this document. The products as well as non-investment incorporated in this document incorporated in this document. The organorus. MORE, Lis associates, their directors are differented in this document. The products as well as non-investment practice and an count transaction in or deal as principal or agent in this document. The products are service to any or section proved solely to onto the transparency and abuil not be transferent on the sale and visco to the analyst,

MOFSL. Motilal Oswal Wealth Management Ltd. (MOVWIL): PMS (Registration No.: INFOUCHEND) is onered through morrisely moderned and object company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services are backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. There is no assurance or guarantee * MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f. August 21, 2018 pursuant to order dated July 30, 2018 issued by Horble National Company Law Tribunal, Mumbai Bench. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for Securities Broking write to grievances@motilaloswal.com